Testing carbon monoxide treatments for acute kidney injury
Early-Stage Preclinical Validation of Carbon Monoxide Prodrugs for Acute Kidney Injury
This study is exploring how carbon monoxide might help protect the kidneys in people with acute kidney injury, using special forms of carbon monoxide that are easy to give, and it aims to find treatments that could eventually be tested in humans.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Georgia State University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-10873220 on NIH RePORTER |
What this research studies
This research investigates the potential of carbon monoxide (CO) as a therapeutic agent for treating acute kidney injury (AKI), a condition with currently limited treatment options. The approach involves developing CO-based prodrugs that can be easily administered and have protective effects on the kidneys. The research will utilize various animal models to validate the effectiveness of these treatments and aims to produce lead compounds that could eventually be tested in humans. By focusing on the organ-protective properties of CO, the study seeks to address a significant unmet medical need in kidney health.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk of or suffering from acute kidney injury.
Not a fit: Patients with chronic kidney disease or those who do not experience acute kidney injury may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients suffering from acute kidney injury.
How similar studies have performed: While the use of carbon monoxide in therapeutic contexts is promising, this specific approach is still in early-stage preclinical validation and has not yet been widely tested in humans.
Where this research is happening
Atlanta, United States
- Georgia State University — Atlanta, United States (Active)
Researchers
- Principal investigator: Wang, Binghe — Georgia State University
- Study coordinator: Wang, Binghe
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.